Solid dispersion of EED inhibitor, oral formulation containing the same, and method for manufacturing the same.

A stable solid dispersion of EED inhibitors with polymer carriers addresses poor solubility and bioavailability, significantly improving therapeutic delivery and efficacy by converting the drug into an amorphous state for enhanced solubility and absorption.

JP2026519124APending Publication Date: 2026-06-11ASCENTAGE PHARMA SUZHOU CO LTD +1
0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
ASCENTAGE PHARMA SUZHOU CO LTD
Filing Date
2024-06-06
Publication Date
2026-06-11

AI Technical Summary

⚠Technical Problem

Existing EED inhibitors, such as compound A, exhibit poor water solubility and bioavailability due to their low dissolution rates in gastrointestinal fluid, limiting their therapeutic effectiveness in treating EED-mediated diseases.

⚗Method used

A stable solid dispersion of EED inhibitors, formulated with polymer carriers like HPMCAS and Eudragit, enhances dissolution and bioavailability by converting the drug into an amorphous state, improving solubility and absorption.

🎯Benefits of technology

The solid dispersion achieves at least 10-fold increase in solubility and stability, ensuring effective therapeutic delivery of EED inhibitors, overcoming limitations of poor water solubility and enhancing treatment efficacy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The present invention relates to the field of pharmaceutical formulations, and more specifically to a solid dispersion containing an extraembryonic ectoderm development (EED) inhibitor having good dissolution and good bioavailability, and a method for producing the same; a solid dispersion composition comprising the solid dispersion and an excipient; an oral formulation comprising the solid dispersion or solid dispersion composition, and a method for producing the same; and the use of the solid dispersion, solid dispersion composition, or oral formulation for the treatment and / or prevention of EED-mediated diseases.
Need to check novelty before this filing date? Find Prior Art